The results reported here are important because, in combination with evidence that LUX inhibits TLR signaling and activation of the NLRP3 inflammasome at concentrations well below those attained in patients, they indicate that LUX as a unique kinase profile quite different from that of IB and suggest that LUX may have activity against autoimmune and inflammatory diseases of multiple types in addition to lymphomas. This evidence concerns the gene NLRP3 and lymphoma.